No Data
Hybio Pharmaceutical (SZSE:300199) Is Carrying A Fair Bit Of Debt
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Investors Push Hybio Pharmaceutical (SZSE:300199) 4.1% Lower This Week, Company's Increasing Losses Might Be to Blame
hybio pharmaceutical (300199.SZ): On October 30th, Liraglutide injection ushered in a large-scale shipment with a total value of 0.103 billion yuan.
Gelonghui November 4th丨hybio pharmaceutical (300199.SZ) stated on the investor interaction platform that on October 30th, the company's Lirarutide Injection received a large-scale delivery, with a total value of 0.103 billion yuan, which was a commercial batch order announced by the company on November 3, 2023. In the future, the company will maintain a long-term exclusive cooperation relationship with Hikma according to the agreement, continue to advance subsequent order deliveries based on the sales market demand in the USA, and receive double-digit sales profit sharing. In addition to this order, the company will gradually issue subsequent orders based on the project progress. Please stay tuned for future order fulfillment.
Hanyu Pharmaceutical: Report for the third quarter of 2024
Hybio Pharmaceutical Gets China Approval for Type 2 Diabetes Injection
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
